Chonluten vs Crystagen — Peptide Comparison

Chonluten vs Crystagen — Peptide Comparison Chonluten vs Crystagen — compare dosing, benefits, safety profiles, side effects, and how they stack. See which peptide is right for you. At a Glance Dose Range Chonluten 5–10 mg Crystagen 1–100 mcg/kg Frequency Once daily Administration Sublingual (enteric-coated capsules) Subcutaneous injection Cycle Length 12+ weeks 8-12 weeks Onset Speed Gradual (3-4 weeks) Evidence Level Limited human trials Efficacy Respiratory Tissue Repair Lung Inflammation Control Age-Related Lung Protection Immune Rejuvenation Healthy Aging Cancer Defense Technical Data Molecular Formula C11H17N3O8 Molecular Weight 319.27 g/mol Half-Life Short plasma half-life typical of tripeptides (minutes to hours); biological effects persist for weeks to months through epigenetic modifications to bronchopulmonary gene expression; metabolized to constituent amino acids Bioavailability Absorbed via intestinal peptide transporters (PepT1) in oral formulation with enteric coating; rapid absorption from subcutaneous injection sites; efficient cellular uptake and nuclear penetration due to ultra-short tripeptide structure CAS Number 75007-24-8 C14H21N3O8 359.3 g/mol Short plasma half-life typical of tripeptides (minutes); biological effects persist for weeks to months through gene expression modifications and thymic microenvironment restoration; metabolized to constituent amino acids Absorbed via intestinal peptide transporters (PepT1/POT and LAT carrier families) when administered orally; rapid absorption from subcutaneous injection sites; efficient cellular uptake due to ultra-short tripeptide structure Not assigned (patented as immunogeroprotective peptide, US8057810B2) Protocols standard 5-10 mg 10-20 days per course For the synthetic peptide form, a dose commonly used in research practice given as an injection under the skin. [6] 1-2 capsules 1-2 times daily with meals 10-30 day course, repeated 2-3 times per year The oral capsule plan used in practice for this bronchopulmonary peptide supplement. [6] 200-400 mcg 10-20 days per course, repeated every 4-6 months Can also be given as an intramuscular injection at a similar dose, used in research practice. [6] 1-2 capsules (10 mg each) 10-30 day course, repeated every 4-6 months The oral capsule plan used in practice. Each Cytogen capsule holds 10 mg, delivering about 200-400 mcg of active peptide per dose. [6] Applications Respiratory health restoration in aging individuals with declining lung function Chonluten is particularly well-suited for individuals focused on respiratory health restoration in aging individuals with declining lung function. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach. Chronic bronchopulmonary conditions requiring tissue-level regenerative support Chonluten is particularly well-suited for individuals focused on chronic bronchopulmonary conditions requiring tissue-level regenerative support. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach. Comprehensive Khavinson bioregulator protocols targeting respiratory and immune function Chonluten is particularly well-suited for individuals focused on comprehensive khavinson bioregulator protocols targeting respiratory and immune function. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach. Geroprotective therapy for lung tissue preservation in elderly populations Chonluten is particularly well-suited for individuals focused on geroprotective therapy for lung tissue preservation in elderly populations. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach. Restoring thymic function and immune competence in aging individuals with immune senescence Crystagen is particularly well-suited for individuals focused on restoring thymic function and immune competence in aging individuals with immune senescence. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach. Comprehensive Khavinson bioregulator protocols for immune and anti-aging support Crystagen is particularly well-suited for individuals focused on comprehensive khavinson bioregulator protocols for immune and anti-aging support. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach. Supporting immune function during and after illness recovery Crystagen is particularly well-suited for individuals focused on supporting immune function during and after illness recovery. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach. Geroprotective immunomodulation to extend healthspan and reduce age-related disease incidence Crystagen is particularly well-suited for individuals focused on geroprotective immunomodulation to extend healthspan and reduce age-related disease incidence. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach. Safety Profile Common Injection site reaction Mild fatigue Transient respiratory changes Mild headache Uncommon Flu-like symptoms Serious No documented serious adverse effects Minor digestive changes Research Status FDA Status Research compound Safety Overview Chonluten is a cartilage-derived peptide extract used primarily in Russian and Eastern European medicine that lacks FDA approval and rigorous clinical safety data. As a poorly defined mixture of collagen peptides and proteoglycans from cartilage tissue, standardization and batch consistency cannot be guaranteed. Potential risks include allergic reactions to connective tissue proteins, contamination from animal tissues, and unknown immunological effects from proteoglycan components. No formal safety assessments, animal toxicology studies by modern standards, or human Phase 1/2 trials exist. Long-term safety outcomes are completely unstudied. Contraindications xKnown hypersensitivity to peptide bioregulators or constituent amino acids (glutamic acid, aspartic acid, glycine) xPregnancy and breastfeeding — insufficient reproductive safety data xActive pulmonary infections requiring immediate medical treatment xSevere immunosuppression without medical supervision — immunomodulatory effects may be unpredictable Crystagen is a crystalline protein extract (likely containing collagen-derived peptides) from animal tissues that is not FDA-approved and has essentially no published safety data in medical literature. As an undefined and poorly characterized biological mixture, batch consistency, sterility, and identity cannot be verified. Potential risks include allergic reactions to animal proteins, contamination from source tissues, and unknown immunological effects. No formal safety assessments, animal studies, toxicology screening, or human clinical trials exist. The product appears to exist primarily in Russian medical markets, and little information about its actual composition or manufacturing is publicly available. xKnown hypersensitivity to peptide bioregulators or constituent amino acids (glutamic acid, aspartic acid, proline) xActive autoimmune disease in flare without physician supervision xOrgan transplant recipients on immunosuppression — potential interference with immunosuppressive regimens Decision Guide Choose Chonluten if... Respiratory health restoration in aging individuals with declining lung function Chronic bronchopulmonary conditions requiring tissue-level regenerative support Comprehensive Khavinson bioregulator protocols targeting respiratory and immune function Geroprotective therapy for lung tissue preservation in elderly populations Choose Crystagen if... Restoring thymic function and immune competence in aging individuals with immune senescence Comprehensive Khavinson bioregulator protocols for immune and anti-aging support Supporting immune function during and after illness recovery Geroprotective immunomodulation to extend healthspan and reduce age-related disease incidence